Your web browser is out of date! We recommend you update your browser to receive the best possible browsing experience.
Download your Brochure
Reserve your place

2017 speaker faculty

Commercial


Anne Beal

Anne Beal

Global Head of Patient Solutions, Sanofi

Read more

Dr. Anne C. Beal, M.D., M.P.H. is the Global Head of Patient Solutions for Sanofi, a global healthcare leader that discovers, develops and distributes therapeutic solutions for patients. In that role, she is responsible for integrating the patient voice and priorities into all aspects of Sanofi’s work to facilitate development of healthcare solutions that truly meet patients’ needs. She is currently based in Paris.

Dr. Beal joined Sanofi from PCORI (Patient-Centered Outcomes Research Institute), where she was the Deputy Executive Director, Chief Officer for Engagement and the inaugural COO. PCORI is a US-based independent organization that supports comparative effectiveness research guided by patients, caregivers and others to help people make informed decisions and improve healthcare delivery and outcomes. Prior to PCORI, Dr. Beal was president of The Aetna Foundation, the charitable arm of Aetna, and previous to that she directed programs on Quality of Care for Underserved Populations at the Commonwealth Fund.

Ruth Wilson

Ruth Wilson

Global Head of Patient Advocacy, Teva

Read more

More information coming soon...

Shabnam Kazmi

Shabnam Kazmi

Vice President, Patient Access & Adherence, Otsuka America

Read more

More information coming soon...

Tom Croce

Tom Croce

Vice President, Global Advocacy Relations, Amgen

Read more

Tom Croce, RPh, oversees development and leads implementation of an integrated strategy involving patient advocacy groups and professional associations. He and the extended Amgen Advocacy Relations team around the globe work collaboratively with these external third-party organizations to align and execute on shared goals across the development life-cycle—from pre-clinical to post-launch and across Amgen’s product portfolio—with the shared vision of improving access to care and health outcomes for patients. Amgen’s new approach to advocacy relations is designed to bring more patient and professional input into how the Company develops and commercializes medicines. Tom and his team put a priority focus on advocating for policies in affiliate markets that are in the best interest of patients.

Tom brings a wealth of experience gained from more than 30 years working in the healthcare industry and with professional associations. He joins Amgen from Shire Pharmaceuticals, where he was head of Global Patient Advocacy. His previous leadership roles have spanned patient and professional advocacy, as well as public affairs, and he has held a leadership role with the American Pharmacists Association.

Jessica Grossman

Jessica Grossman

Chief Executive Officer, Medicines360

Read more

Dr. Grossman is an experienced and visionary leader in women's health. Currently she is CEO of Medicines360, a non-profit pharmaceutical organization. Medicines360 recently received FDA approval for LILETTA a 52mg hormonal IUD. Previously, she was CEO and President at Sense4Baby, Inc. that was sold to AirStrip, LLC. Prior to that she was a medical director at Ethicon Endo-Surgery, a Johnson and Johnson company. Dr. Grossman was also a Board Member at Medicines360, a non-profit pharmaceutical company. In addition, Dr. Grossman was the founder and President of Gynesonics, an early stage medical device company focused on minimally invasive solutions for women’s health where she raised over $20 million in venture capital financing.

Katherine Capperella

Katherine Capperella

Global Patient Engagement Leader, Janssen

Read more

As global head of patient engagement for Janssen, Katherine leads a cross-functional team responsible for developing and driving patient engagement strategy and measuring progress over time.  She and her team are focused on leading Janssen to incorporate direct patient voice early and throughout the entire product lifecycle, beginning with disease area strategies and including product development, formulation decisions and clinical trial strategies.  Katherine has over 20 years of experience at Johnson & Johnson in roles of increasing responsibility, most recently as global commercial vice president for the pain API business.

Gabriela Mondino

Gabriela Mondino

Head of US Public Affairs, Multiple Sclerosis, Sanofi Genzyme

Read more

Gabriela Mondino is dedicated to delivering value to patients so they can focus more on living life and less on their disease. For over fifteen years, she has been devoted to understanding needs and providing solutions to physicians and patients.

Gabriela currently leads the Public Affairs function for Multiple Sclerosis at Sanofi Genzyme. She joined Sanofi in 2013 as Global Marketing Director in osteoarthritis, where she led the shift to patient centricity, integrating the voice of the patient into the business strategy. She built patient marketing capabilities within affiliates and supported the implementation of patient activation programs.

Prior to Sanofi, Gabriela held global marketing positions at Baxter Healthcare, Glaxosmithkline, Kraft Foods and Kimberly-Clark. She speaks four languages and has lived in Argentina, France and the US; her work experience covers five continents and over forty countries.

Originally from Argentina, Gabriela earned her bachelor’s degree at Lawrence University and her Master of Business Administration at Thunderbird School of Global Management. In addition, Gabriela is the founder of VISIONAR, a philanthropic organization that provides scholarships and mentorship to college students in Argentina.

Doug Noland

Doug Noland

Patient Experience, Executive Director, Astellas

Read more

Doug Noland is the head of Astellas’ newly established Patient Experience organization. He is responsible for delivering results for patients by accelerating the pace and scope of associated organizational change to ensure Astellas’ market leadership in the area of patient experience. He is responsible for engaging with all facets of the organization to align on a true north definition of patient experience to ensure that all strategies, tactics, policies and procedures work across all functions to facilitate the delivery of high quality patient experience and outcomes.

Prior to his current role, Doug led the development and implementation of Astellas’ business-to-business model and comprehensive end-to-end disease state solutions to help Integrated Health Systems deliver improved patient care. He also established Astellas’ Commercial Innovation and Effectiveness group during which time he worked with Astellas president team to drive results through broad and sustainable organizational change.

Dawn DiCandilo

Dawn DiCandilo

Patient Centricity Excellence Director, AstraZeneca

Read more

Dawn has nineteen years of pharma industry experience with a focus and passion for the Medical Affairs function.  14 of those years were spent in the US market in roles within Medical Affairs operations.  In 2012, she helped establish Global Medical Excellence in AstraZeneca and then went to Japan for 3 years to establish Medical Excellence there.  Much of her experience centered around driving an increase in the contribution and value that Medical Affairs brings through strategic planning, metrics, capability development and communication strategies.

In her role as PaCe Excellence Director, Dawn provides strategic direction and leadership of the capability programs to elevate patient insight and engagement skills to help teams effectively understand patient needs and co-create solutions with patients. She facilitates enterprise-level collaborations to develop robust patient-oriented risk management and governance frameworks.

Marilyn Metcalf

Marilyn Metcalf

Head, Center of Innovation & Patient Engagement Lead, GlaxoSmithKline

Read more

Dr. Metcalf is a Patient Engagement Lead at GSK. She and her Patients in Partnership colleagues lead GSK’s work developing medicines with patients, to meet their health goals. She is a member of GSK’s Global Safety Board and participates in a number of alliances including Patient Focused Medicine Development; Patients as Partners; FasterCures; National Health Council; National Academies of Sciences, Engineering, and Medicine; and TransCelerate.

Previously she was Family Health International’s project director for an NIH master contract for HIV vaccine research, primarily in developing countries. She studied the health economics and quality of life effects of HIV therapies at the former GlaxoWellcome. She moved to the UK to build GSK’s international Decision Sciences team. Upon returning to the US, she led Centocor’s R&D portfolio management team, formed GSK’s Benefit Risk Evaluation team, then led the Pharmacovigilance Centre of Innovation. Her current role began in June 2017.

Christine MacCracken

Christine MacCracken

Director, Patient Support, Janssen

Read more

Christine MacCracken is Director, Patient Support at the Janssen Pharmaceutical Companies of Johnson and Johnson where she leads strategic identification and implementation of patient-centered initiatives. In this role, she serves as key liaison to New York University School of Medicine and the Compassionate Use Advisory Committee (CompAC). Her focus is on raising organizational awareness around hearing the voice of the patient and recognizing “Every Patient is a Person First”.

Prior to joining the Johnson & Johnson Family of Companies in 2015, Christine was Senior Director, Business Insights at the National Comprehensive Cancer Network (NCCN).In support of people with cancer and the providers who treat them, she closely collaborated with industry, state oncology societies and advocacy groups to disseminate NCCN treatment information through health technology platforms as well as market and outcome research programs.

Christine’s strong passion around hearing the voice of the patient began at the Children’s Hospital of Philadelphia where she was an oncology nurse treating families with life changing diagnoses. With patients and their experience front of mind, she developed an interest in research and joined Radiation Therapy Oncology Group (RTOG) with a focus on quality of life studies. Bridging this interest with pharmaceutical development, she later joined Merck & Co., Inc. with increasing roles of responsibility in clinical research and academic affairs, ultimately sharing her collective experience as an adjunct professor.

Christine resides outside of Philadelphia with husband Tim, and the luckiest dog on earth, Jack. She holds a Bachelor of Science, Nursing from Holy Family University and Master’s Degree, Health Education from Arcadia University.

Jaye Bea Smalley

Jaye Bea Smalley

Associate Director, Patient Advocacy and Professional Relations - Patient Engagement, Boehringer Ingelheim

Read more

More information coming soon...

Madeline Geday

Madeline Geday

Associate Director, Patient and Stakeholder Engagement Lead, Merck

Read more

Madeline is an Associate Director for the Global Trial Optimization Group within GO (Global Operations) at Merck and Co., Inc. She serves as Patient and Stakeholder Engagement Lead for her organization. Madeline is responsible for optimizing clinical trial feasibility and execution through integrated data-driven expert analysis and recommendations, while promoting its engagement, development, and opportunities for innovation in recruitment and retention.

Madeline joined Merck in 2004. She began her work as a Medical Program Clinical Specialist working on several insomnia programs in clinical neuroscience with a focus on patient recruitment. Madeline joined Global Trial Optimization in 2006 where she has spearheaded dozens of patient recruitment initiatives, served as Therapeutic Area lead for Neuroscience, Ophthalmology, Hematology and Multiple Myeloma as well as Process Owner and Subject Matter Expert for the department. While at Merck, she has helped launch the Clinical Trials Microsite of merck.com; has lead several voice of the patient projects; and has served as an industry expert in the field of recruitment and retention. Most recently, she has been appointed to lead the initiative for Patient and Stakeholder Engagement within the Global Clinical Trial Organization with the intent of capturing the voice of the patient into operational aspects of clinical trial design, feasibility, and recruitment and retention. She also works on several collaborative projects surrounding Diversity in Clinical Trials. Trained in Health Literacy principles, she has used her knowledge and expertise to champion changes to patient facing materials to ensure health literacy for clinical trial participants and their families.

Prior to Merck, Madeline held positions in Business Development, Education, and in Clinical Research as a CRA Associate.

Madeline received her B.S. in Psychology and Health/Exercise Physiology from Ursinus College in Collegeville, Pennsylvania and is pursuing graduate coursework in Marketing from Temple University.

Barbara Wuebbels

Barbara Wuebbels

Vice President of Global Patient Relations, Audentes Therapeutics

Read more

Barbara has been involved in patient advocacy activities for patients with rare diseases for the past 15 years at Ucyclyd Pharma and BioMarin. She joined Audentes Therapeutics as Vice President of Patient Advocacy and Medical Affairs in 2013. Currently she is the Vice President of Global Patient Relations. She has been actively involved with the National Organization of Rare Diseases, International Conference of Rare Disorders, and the Global Genes Project. Currently she serves on the Board of the Batten’s Disease Support and Research Association. Additionally she is the Chair and founding board member of the Professional Patient Advocates in the Life Sciences.

She holds Bachelor’s and Masters degrees in nursing.

Aaron Mitchell

Aaron Mitchell

Managing Principal, ZS

Read more

Aaron Mitchell is a Managing Principal and the global lead for ZS’s R&D excellence practice, based in Zurich, Switzerland. He partners with clients to strengthen the value of their pipelines, optimize the execution of clinical trials, drive the effective use of real-world evidence, and improve medical and scientific engagement. A key area of focus for Aaron is patient-centric drug development, including optimizing clinical trials for patients and leveraging real-world evidence to support product development. Aaron joined ZS in January of 2003. Prior to ZS Aaron was a manager for Deloitte, providing strategic consulting services to clients in a range of industries including financial services consumer products retail and healthcare. He has a Master of Business Administration degree from the Haas School of Business at University of California Berkeley and a Bachelor of Science degree in mechanical engineering from the United States Military Academy at West Point.

Hensley Evans

Hensley Evans

Principal, ZS

Read more

Hensley Evans is a Principal based in New York and leads ZS’s patient marketing strategy practice. Hensley has developed and implemented strategic solutions that combine marketing efforts with consumer health support programs for pharmaceutical, biotech, over-the-counter and provider clients, and has driven health and wellness initiatives in the consumer goods industry. Hensley holds a B.A. in Economics from Duke University and an M.B.A from the University of Pennsylvania’s Wharton School of Business.

Roger Sawhney

Roger Sawhney

Senior Vice President of Life Sciences Strategy and Business Development, Outcome Health

Read more

As Senior Vice President of Life Sciences Strategy and Business Development, Roger leads Outcome Health’s efforts to develop relationships and partnerships with the world’s leading life sciences companies. With 20 years of experience in the biopharmaceutical industry, Roger focuses on developing, coordinating and implementing strategies to help Outcome Health’s brand partners meet their business goals.

Roger was previously a partner in Bain and Company’s global healthcare and private equity practices, where he enabled healthcare companies to drive strategic position and competitive advantage. He also worked at Novartis as senior vice president and global head of corporate strategy, leading the company’s long range planning, business growth and eHealth efforts, as well as emerging market strategy. He serves on the Board of Directors for the New York Institute of Technology (NYIT).

Heather Erickson

Heather Erickson

Chief of Staff, Sangamo Therapeutics

Read more

More information coming soon...

Clinical


Gavin Corcoran

Gavin Corcoran

Chief Medical Officer, Allergan

Read more

More information coming soon...

Cathryn Clary

Cathryn Clary

Global Head, Patient Affairs and Policy, Chief Medical Office, Novartis

Read more

Cathryn M. Clary, MD is Global Head of Patient Affairs and Policy in the Chief Medical & Patient Safety Office, Novartis Global Drug Development. In this role, Cathryn is responsible for ensuring the implementation of Patient Focused Drug Development across Novartis and developing and implementing patient centered policies.

Cathryn received her MD degree from the University of Missouri-Columbia and completed psychiatric residency training at the University of Pennsylvania in Philadelphia.  She practiced psychiatry for 13 years in Delaware, staying actively engaged in clinical research through her membership in the University of Pennsylvania Psychopharmacology Research group.

After receiving an MBA degree from the University of Delaware, Cathryn joined Pfizer in 1996 as Medical Director. Her 13 year career at Pfizer was one of continued advancement and in her last four years, she served as SVP of the US Medical group.. supporting a large portfolio. After leaving Pfizer, Cathryn took a role as Head, US Clinical Development and Medical Affairs at Ipsen, a French biopharmaceutical company, for three years, before joining Novartis. 

Throughout her career, Cathryn has been interested and engaged in public affairs and public speaking on behalf of patients. This has led to engagements such as Congressional testimony on publications of pharmaceutical sponsored research in 2004 and presentations before the Institute of Medicine. She is a Distinguished Life Fellow of the American Psychiatric Association.  Cathryn has also published widely, mainly in psychiatric journals.

Martin Mendoza

Martin Mendoza

Director of Extramural Research, Office of Minority Health, FDA

Read more

Martin Mendoza, PhD serves as Director of Extramural Research in FDA’s Office of Minority Health (OMH) where he oversees OMH’s extramural research grant program. Martin has spoken before Congress and other audiences in support of OMH’s programs, has authored numerous Congressionally-mandated reports, and is primary author for OMH’s recent FDA guidance document Collection of Race and Ethnicity Data in Clinical Trials. Prior to FDA, he spent several years in NIH’s extramural and intramural research programs, with work ranging from neurological clinical trials, pediatric oncology research, to the Human Genome Project. Martin received his doctorate in cancer biology from Johns Hopkins University.

Divya Mishra Aidoud

Divya Mishra Aidoud

Associate Director, New Product Planning Market Research, Sanofi

Read more

Divya Aidoud is passionate about generating market knowledge and authentic understanding of consumers to help businesses create offerings that address real problems. For over 16 years, she has led the development of strategic learning plans that keep the consumer’s voice, center-stage.

Divya is currently Associate Director, New Product Planning Market Research for Sanofi Genzyme. Before this, she was Director, Global Market Research and Portfolio Management for Sanofi Biosurgery. In this role she developed a New Product Development commercial process and the first Global Patient Journey Playbook. Prior to Sanofi, Divya held global marketing research roles at Keurig, Proctor & Gamble, Boehringer Ingelheim, and Sunovian.

Divya holds a B.A. in Chemistry from Wellesley College and an MBA from Babson College. She is an avid yogi practitioner and is enjoying being a first-time mom.

Frank Spinelli

Frank Spinelli

Medical Director, Patient Affairs, US, ViiV Healthcare

Read more

More information coming soon...

Ramana Sonty

Ramana Sonty

Director of Strategy, Global Medical Organization, Janssen

Read more

Ramana Sonty, MBBS, PhD, is a Director of Strategy, in the Janssen Global Medical Organization.

Dr. Sonty is a J&J leader who helped launch Janssen’s innovative pilot with NYU called CompAC (Compassionate Use Advisory Committee). The CompAC is a first-of-its-kind independent, expert body providing recommendations on compassionate use requests. The model been expanded to all of Janssen’s assets and is under consideration for adoption more broadly across the industry. Pilot findings have been published in Nature and JAMA.  He has trained in Medicine and Neuroscience.

Debra Reinhard

Debra Reinhard

Lead, Translational Medicine Enabling Solutions, Bristol-Myers Squibb

Read more

A sought-after speaker and subject matter expert with over 28 years in the Pharmaceutical industry, Deb’s career has spanned Corporate and R&D Finance and strategy, as well as broad Informatics roles in support of R&D.  As Head of Translational Medicine Enabling Solutions, she leads a growing organization that plans and executes translational medicine strategies, integrating Discovery, Clinical Development and Translational Research.  She is responsible for the BMS biorepository, redesigning informed consent processes and tools, and ensuring robust operations across all lab partners.  Deb is a core member of TransCelerate’s eConsent initiative creating an industry-aligned position on consent processes and technologies.

Joseph Kim

Joseph Kim

Senior Advisor, Clinical Innovation, Eli Lilly and Company

Read more

Joseph Kim serves as a Senior Advisor in Clinical Innovation at Lilly, focusing on developing and implementing innovative patient engagement solutions. He has spent over 18 years in the Pharma industry utilizing a unique approach that integrates his experiences working for Sponsors such as Shire and Merck, CROs, and technology vendors. He has a robust combination of experience that includes early and late phase clinical research, and a well-known history of innovation in the clinical research industry, recognized as one of “Top 100 individuals on the 2015 MedicineMakers Power List, and “20 Innovators Changing the Face of the Clinical Trials Industry” by CenterWatch in 2013.  He holds a BS in Molecular Biology from Lehigh University and an MBA from Villanova. He can be reached at kim_joseph_p@lilly.com and on Twitter

Patricia Cunningham

Patricia Cunningham

Associate Director Health Information Technology, Boehringer Ingelheim

Read more

Ms. Cunningham has approximately 30 years of progressive experience in health information management and technology. She has a Masters Degree in Health Informatics, is a Certified Registered Health Information Administrator and is also Certified in Healthcare Privacy and Security. Her extensive career and experience includes implementing numerous EHR platforms in diverse healthcare settings; leading Health Information Management and Technology Teams; serving as the organization-wide Privacy Officer in a large academic medical center and serving as the Chief Technology Officer for the State of Illinois’ Health Information Exchange. In her current role as the Associate Director of Health IT at Boehringer-Ingeheim Pharmaceuticals, she is responsible for orchestrating digital processes for organizational population health initiatives.

Stephen Yates

Stephen Yates

Clinical Program Director and Head, Patient Engagement Strategy, UCB

Read more

More information coming soon...

Daniele D’Ambrosio

Daniele D’Ambrosio

Senior Director, Clinical Science Program Head, Actelion

Read more

Daniele D'Ambrosio, M.D., Ph.D., currently leads Actelion's clinical team developing ponesimod for the treatment of multiple sclerosis. Daniele joined Actelion in 2009 and was appointed Senior Director, Clinical Science Program Head in 2011. In his function, he has provided scientific and management leadership to Actelion's clinical programs in autoimmune diseases. Prior to joining Actelion, Daniele held various R&D positions in biotech and leading pharmaceutical companies Roche and Novartis.

Daniele earned his M.D. and Ph.D. in Experimental Medicine and Immunology from La Sapienza University, Rome, Italy. He completed a postdoctoral fellowship in Immunology at the National Jewish Hospital in Denver, has published more than 60 scientific articles, and is inventor on one issued patent. Daniele has served on the Editorial Board of British Journal of Pharmacology, and has held a Professorship at the School of medical, molecular and cellular biotechnologies at Vita Salute San Raffaele University, Milano, Italia

Luther Clark

Luther Clark

Global Director, Scientific, Medical and Patient Perspective, Merck

Read more

Dr. Luther T. Clark is Global Director, Scientific Medical and Patient Perspective (SMPP) in the Office of the Chief Patient Officer (OCPO) at Merck. In this role, he supports the needs of the CPO by (1) gathering internal and external scientific and medical information to assist with decision-making at the highest levels and (2) collaborating across Merck to help increase the voice of patients, directly and indirectly into decision-making across the enterprise. He is a key member of the team that champions the OCPO’s Health Care Equities Strategic Initiative (including promotion of health literacy and research diversity) and chairs the Health Literacy Investigator Initiated Studies Research Committee.

Prior to joining Merck, Dr. Clark was Chief of the Division of Cardiovascular Medicine and Director of the National Institutes of Health (NIH) funded Brooklyn Health Disparities Research Center.

Dr. Clark earned his Bachelor of Arts degree from Harvard College and his Medical degree from Harvard Medical School. He has authored more than 100 publications, edited and was principal contributor to the textbook, Cardiovascular Disease and Diabetes (McGraw-Hill 2007).

Mary Elmer

Mary Elmer

Associate Director, Global Patient Engagement Strategy Office, Merck

Read more

Mary Elmer leads a team for the global patient engagement program at the office for the Chief Patient Officer at Merck & Co., Inc. This group is actively involved in bringing the voice of the patient into the drug development process at Merck through strong collaborative partnerships with patients and organizations serving patients. Mary is a board-certified nurse practitioner with over 18 years of experience at Merck, working in all phases of drug development and implementing global strategic initiatives. Mary is a member of the Global Diversity and Inclusion council at Merck and co-leads the diversity in US clinical trials initiative, which seeks to ensure our clinical trials are representative of diverse patient groups. Mary is a member of TransCelerate Biopharma, and leads a work stream on patient engagement.

Mary obtained her Master of Science in Nursing degree from the University of Pennsylvania. She is a Six Sigma green belt who has experience in executing organizational change and cross-company initiatives, such as implementing clinical trial data sharing at Merck, in alignment with trade organizations (EFPIA/PHRMA) and regulatory bodies.

Martin Collyer

Martin Collyer

Chief Operating Officer Patient Recruitment, Bioclinica

Read more

 Martin Collyer is a senior healthcare and life sciences executive with more than 20 years of experience and a strong operations and finance background.

As COO of Bioclinica’s Patient Recruitment & Retention division, Martin enables organizations to expedite the enrollment of patients into clinical trials utilizing therapeutically-aligned global patient engagement platforms and digital methodologies.

Prior to joining Bioclinica in 2016 he was with Hitachi for four years solving big data challenges.

Susan Bartlett

Susan Bartlett

Principal, Bridgeable

Read more

Susan Bartlett is a service designer and business strategist at Bridgeable, where she helps organizations transform their business using service design. Susan leads multidisciplinary design teams as they understand the complex interactions people have with the world around them, and work to make those interactions more meaningful and effective. Her projects emphasize co-creation with a wide array of stakeholders, applying a holistic, systems-thinking lens to problem solving, and using service design to effect organizational change.

Martha Brumfield

Martha Brumfield

President and CEO, Critical Path Institute

Read more

Martha A. Brumfield, PhD, is President and CEO of Critical Path Institute, which advances drug development and regulatory science. Brumfield brings 20 years of experience from Pfizer Inc., where she was SVP, Worldwide Regulatory Affairs and Quality Assurance. She chaired the board for RAPS, and currently serves as Secretary on the Board of I-ACT for Children, and on the steering committee for Harvard/Brigham & Women’s Multi-Regional Clinical Trials Initiative. Brumfield earned a BS and MS in chemistry from Virginia Commonwealth University, a PhD in organic chemistry from the University of Maryland, served as a postdoctoral fellow at The Rockefeller University, and holds an appointment as Assistant Professor, University of Arizona College of Pharmacy.

Kelly Franchetti RN,CCRN,CEN

Kelly Franchetti RN,CCRN,CEN

Vice President, Global Patients Insights and Engagement, Patient-Centered Sciences, Mapi

Read more

A prolific author, presenter, lecturer, and thought leader in the realm of patient recruitment and retention, Kelly Franchetti leads Mapi’s Patient Insight and Engagement team and brings extensive experience in partnering with patient advocacy, and clinical research with a specialty in Rare Disease programs.

She is a leading developer of Patient Engagement solutions in the world of both clinical research and in therapeutic practice.

Ms. Franchetti has two decades of direct patient experience, gained in both hospital and industry settings, including CROs, healthcare technology, patient research, and hands-on patient care across multiple therapeutic areas.

Ms. Franchetti was an active critical care Registered Nurse for over 18 years and an experienced caregiver for children with rare disease for over 20 years. This experience translates into a keen understanding of how patients think regarding their treatment, giving her a singular perspective regarding the best way to approach patients and Health Care Practitioners. She maintains her nursing status at Temple Hospital to continue to grow her knowledge base regarding patient care.

In conjunction with her nursing career, Ms. Franchetti founded the New Jersey State Coalition of Safe Kids Worldwide, where she worked directly with both local and national legislators and regulators to change laws to enhance safety for children throughout the state and North America.

Ms. Franchetti has been involved in the development and moderation of advisory boards as well as patient, HCP, and KOL forums. She also has experience collaborating with Patient and Clinical Advocacy groups. Her experience allows her to provide significant insights into how patients regard their treatment options and how to best approach patient recruitment and retention strategies.

Franchetti currently sits on Mapi’s Patient Initiative ommittee along with the industry’s foremost leaders on Patient Centered Medical Affairs, Patient Centered Outcomes, and Research Experts from the Mapi Trust.

Patients & Advocates


Cindy Geoghegan

Cindy Geoghegan

Principal, Patient and Partners LLC

Read more

A patient advocate and cancer survivor with decades of health policy, communications and capacity-building experience, Cindy Geoghegan founded Patient & Partners to ensure that the patient perspective is strategically integrated into industry, academic, government and non-profit efforts focused on patient outcomes and clinical benefit. She has founded, transformed and grown several patient-led non-profit organizations, and represents the patient perspective on research projects sponsored by government, academia and industry. She currently serves as an individual patient/caregiver representative on CTTI’s Steering Committee and as a team lead for CTTI’s Mobile Clinical Trials Stakeholder Perceptions project.

Grace Cordovano

Grace Cordovano

CEO, Enlightening Results

Read more

Upon recognizing significant unmet needs and challenges in patients’ journeys throughout their cancer diagnosis, Dr. Grace Cordovano founded Enlightening Results, LLC in 2010. As the culmination of her life’s experiential learning and education, Dr. Cordovano is dedicated to fostering private, personalized patient advocacy services, specializing in the cancer arena.  She strategically and empathetically guides her clients through survivorship or end-of-life care, ensuring they are armed with the most pertinent, medically credible, easy to understand information so as to make empowered decisions about their care. Grace is a firm believer in the continuous advancement and improvement of cancer patient experiences through the infusion of empathic design and thinking into current healthcare paradigms. A frequent questioner of the status quo, she leaves no stone or process unturned in her quest to improve overall patient experiences across the continuum of patient care. She's motivated to have patient and caregiver stories included throughout the entire healthcare ecosystem and considers herself a patient voice activator. Grace operates as part rocket scientist, part healthcare MacGyver, a dash of Tinkerbelle (because everything is better when left with a little sparkle), topped off with a whole lot of coffee. Grace is a proud member of the Alliance of Professional Health Advocates (APHA), the premier, international organization of independent professional patient advocates.

Heidi Floyd

Heidi Floyd

Author, Patient, Advocate, Speaker

Read more

As individuals are diagnosed with cancer, many immediately seek to make a connection with others for help.  Heidi Floyd has become that resource for many. As an author/speaker/patient/advocate, she is able to lean on myriad of NGOs and fellow patients in her network. Heidi has the ability to lean in and listen to true needs – from caregivers and corporations who want to help, but aren’t sure where to begin. Connecting those who need with those who can assist is her true passion, and has done so worldwide. She’s addressed venues as varied as Google to classrooms of 6.

Levi Gershkowitz

Levi Gershkowitz

Founder and Executive Director, Living in the Light LLC

Read more

As a compassionate writer and photographer with a love for people and the stories they carry, Levi is the Founder and Executive Director of Living in the Light, an advocacy corporation that utilizes the potency of photography, filmmaking and compelling personal narratives to educate about the realities of living with a rare disease and the unprecedented impact this has on families and daily life. This distinct concentration grew out of an understanding that the rare disease community is comprised of many people with many voices, while at the heart lies a unified experience of deep resilience and unique wisdom.

Michael Mittelman

Michael Mittelman

VP Patient Advocacy & Strategic Partnerships, American Living Organ Donor Fund

Read more

Michael Mittelman is currently the Patient Editor at The BMJ and a Co-Founder and VP of Patient Advocacy and Strategic Partnerships of the American Living Organ Donor Fund, a patient rights group focused on helping living organ donors in their quest to become a donor. He is the former CEO and Co-Founder of PHmHealth, a digital health company focused on post-acute care and compliance. His experience as a patient spans over 3 decades. He is a 3-time kidney transplant recipient with other chronic conditions. Michael was invited to testify/advocate before the FDA and serves as PCORI (Patient-Centered Outcomes Research Institute) patient representative. Additionally, he serves on the steering committee of a PCORI-funded initiative. He has also overseen the mobile app development taskforce and the data governance taskforce for the same PCORI-funded initiative, the NephCure Kidney Network. Michael is a tireless, independent patient advocate and a healthcare strategist. He strongly believes that patients should play integral roles in healthcare companies and government agencies.

Michael holds an MBA in Healthcare Management from the Fox School of Business at Temple University.  He also has a BA in Biological Basis of Behavior from the University of Pennsylvania. He is a published author, with his latest piece in the American Journal of Transplantation.

Marla Jan Wexler

MarlaJan Wexler

Patient, Lupus Advocate and Blogger, Luck Fupus

Read more

MarlaJan Wexler is 35 years old, was born with a complex congenital heart defect, and had 4 open-heart surgeries by the time she was 6. She went from pediatric cardiac ICU patient to pediatric cardiac ICU nurse until being diagnosed with systemic lupus erythematous (lupus). Due to complications from the disease, she was forced her to give up her nursing career. Since 2008 she has been diagnosed with lupus and multiple overlapping autoimmune diseases, cervical cancer, and underwent a double mastectomy December 2014 after a lump was found in her breast.

She’s the creator and author of the blog Luck Fupus (www.luckfupus.com) which she writes about the day-to-day and long-term struggles of living with multiple chronic illnesses. She’s know for her humorous, non-sugar coated, keep-it-real style of writing. Her blog was used as a platform to help her become a patient leader and influencer, and she now travels the country attending healthcare conferences, speaking publicly sharing her story, educating and advocating for patients across the globe.

Nadia Bodkin

Nadia Bodkin

Board Member, EDSers United Foundation

Read more

Nadia is a seasoned rare disease advocate. She served as the chairperson for Rare NJ and was the Executive Director for RDUF. She also founded and currently directs EDSers United, and is the current Corporate Engagement Manager for the Jansen’s Foundation. Nadia earned her Pharm.D. and Masters in Genetics from Rutgers University. In addition to leading the community outreach and engagement efforts for LITL, Nadia also formulates and implements collaborative programs specific to the particularities of the rare disease community for several groups dedicated to serving rare disease stakeholders.

Nancy Roach

Nancy Roach

Founder, Fight Colorectal Cancer

Read more

A cancer survivor and advocate, Nancy knows how to make a difference. Nancy has been involved with the colorectal cancer community since 1996 when her mother-in-law was diagnosed with rectal cancer, and was a co-founder of the Colon Cancer Alliance in 1999. She works with the gastrointestinal research community, government agencies, elected officials and corporations, always pushing on behalf of people touched by colorectal cancer. She has been affiliated with the National Cancer Institute Clinical Trials Working Group, GI Steering Committee and SPORE program, served on the Scientific Advisory Board for StandUp To Cancer along with the editorial board of the American Association of Cancer Research’s consumer magazine. She founded Fight Colorectal Cancer in 2005 in order to provide focus, infrastructure and support to the growing colorectal cancer advocacy movement. Nancy has been an active board member since 2005.

James Metcalf

James Metcalf

Patient

Read more

James resides in southeast Missouri and is passionate about clinical research.  He first participated in a clinical trial on asthma which was investigating the efficacy of a new inhaler.  Since then, he has participated in approximately 32 clinical trials covering everything from pain management techniques to allergy studies though a university “Volunteer for Health” program.   Having lost his mom to mixed dementia, he is very involved in dementia research and most recently has enrolled in a study designed to detect Alzheimer’s dementia in its earliest stage.  James also volunteers his time to participate on TransCelerate’s patient advisory boards, where he has the opportunity to provide his feedback, insights and ideas on solutions aimed at creating better informed patients and lessening the burden for patients in clinical trials.

All Speakers


Anne Beal

Anne Beal

Global Head of Patient Solutions, Sanofi

Read more

Dr. Anne C. Beal, M.D., M.P.H. is the Global Head of Patient Solutions for Sanofi, a global healthcare leader that discovers, develops and distributes therapeutic solutions for patients. In that role, she is responsible for integrating the patient voice and priorities into all aspects of Sanofi’s work to facilitate development of healthcare solutions that truly meet patients’ needs. She is currently based in Paris.

Dr. Beal joined Sanofi from PCORI (Patient-Centered Outcomes Research Institute), where she was the Deputy Executive Director, Chief Officer for Engagement and the inaugural COO. PCORI is a US-based independent organization that supports comparative effectiveness research guided by patients, caregivers and others to help people make informed decisions and improve healthcare delivery and outcomes. Prior to PCORI, Dr. Beal was president of The Aetna Foundation, the charitable arm of Aetna, and previous to that she directed programs on Quality of Care for Underserved Populations at the Commonwealth Fund.

Ruth Wilson

Ruth Wilson

Global Head of Patient Advocacy, Teva

Read more

More information coming soon...

Shabnam Kazmi

Shabnam Kazmi

Vice President, Patient Access & Adherence, Otsuka America

Read more

More information coming soon...

Tom Croce

Tom Croce

Vice President, Global Advocacy Relations, Amgen

Read more

Tom Croce, RPh, oversees development and leads implementation of an integrated strategy involving patient advocacy groups and professional associations. He and the extended Amgen Advocacy Relations team around the globe work collaboratively with these external third-party organizations to align and execute on shared goals across the development life-cycle—from pre-clinical to post-launch and across Amgen’s product portfolio—with the shared vision of improving access to care and health outcomes for patients. Amgen’s new approach to advocacy relations is designed to bring more patient and professional input into how the Company develops and commercializes medicines. Tom and his team put a priority focus on advocating for policies in affiliate markets that are in the best interest of patients.

Tom brings a wealth of experience gained from more than 30 years working in the healthcare industry and with professional associations. He joins Amgen from Shire Pharmaceuticals, where he was head of Global Patient Advocacy. His previous leadership roles have spanned patient and professional advocacy, as well as public affairs, and he has held a leadership role with the American Pharmacists Association.

Jessica Grossman

Jessica Grossman

Chief Executive Officer, Medicines360

Read more

Dr. Grossman is an experienced and visionary leader in women's health. Currently she is CEO of Medicines360, a non-profit pharmaceutical organization. Medicines360 recently received FDA approval for LILETTA a 52mg hormonal IUD. Previously, she was CEO and President at Sense4Baby, Inc. that was sold to AirStrip, LLC. Prior to that she was a medical director at Ethicon Endo-Surgery, a Johnson and Johnson company. Dr. Grossman was also a Board Member at Medicines360, a non-profit pharmaceutical company. In addition, Dr. Grossman was the founder and President of Gynesonics, an early stage medical device company focused on minimally invasive solutions for women’s health where she raised over $20 million in venture capital financing.

Katherine Capperella

Katherine Capperella

Global Patient Engagement Leader, Janssen

Read more

As global head of patient engagement for Janssen, Katherine leads a cross-functional team responsible for developing and driving patient engagement strategy and measuring progress over time.  She and her team are focused on leading Janssen to incorporate direct patient voice early and throughout the entire product lifecycle, beginning with disease area strategies and including product development, formulation decisions and clinical trial strategies.  Katherine has over 20 years of experience at Johnson & Johnson in roles of increasing responsibility, most recently as global commercial vice president for the pain API business.

Gabriela Mondino

Gabriela Mondino

Head of US Public Affairs, Multiple Sclerosis, Sanofi Genzyme

Read more

Gabriela Mondino is dedicated to delivering value to patients so they can focus more on living life and less on their disease. For over fifteen years, she has been devoted to understanding needs and providing solutions to physicians and patients.

Gabriela currently leads the Public Affairs function for Multiple Sclerosis at Sanofi Genzyme. She joined Sanofi in 2013 as Global Marketing Director in osteoarthritis, where she led the shift to patient centricity, integrating the voice of the patient into the business strategy. She built patient marketing capabilities within affiliates and supported the implementation of patient activation programs.

Prior to Sanofi, Gabriela held global marketing positions at Baxter Healthcare, Glaxosmithkline, Kraft Foods and Kimberly-Clark. She speaks four languages and has lived in Argentina, France and the US; her work experience covers five continents and over forty countries.

Originally from Argentina, Gabriela earned her bachelor’s degree at Lawrence University and her Master of Business Administration at Thunderbird School of Global Management. In addition, Gabriela is the founder of VISIONAR, a philanthropic organization that provides scholarships and mentorship to college students in Argentina.

Doug Noland

Doug Noland

Patient Experience, Executive Director, Astellas

Read more

Doug Noland is the head of Astellas’ newly established Patient Experience organization. He is responsible for delivering results for patients by accelerating the pace and scope of associated organizational change to ensure Astellas’ market leadership in the area of patient experience. He is responsible for engaging with all facets of the organization to align on a true north definition of patient experience to ensure that all strategies, tactics, policies and procedures work across all functions to facilitate the delivery of high quality patient experience and outcomes.

Prior to his current role, Doug led the development and implementation of Astellas’ business-to-business model and comprehensive end-to-end disease state solutions to help Integrated Health Systems deliver improved patient care. He also established Astellas’ Commercial Innovation and Effectiveness group during which time he worked with Astellas president team to drive results through broad and sustainable organizational change.

Dawn DiCandilo

Dawn DiCandilo

Patient Centricity Excellence Director, AstraZeneca

Read more

Dawn has nineteen years of pharma industry experience with a focus and passion for the Medical Affairs function.  14 of those years were spent in the US market in roles within Medical Affairs operations.  In 2012, she helped establish Global Medical Excellence in AstraZeneca and then went to Japan for 3 years to establish Medical Excellence there.  Much of her experience centered around driving an increase in the contribution and value that Medical Affairs brings through strategic planning, metrics, capability development and communication strategies.

In her role as PaCe Excellence Director, Dawn provides strategic direction and leadership of the capability programs to elevate patient insight and engagement skills to help teams effectively understand patient needs and co-create solutions with patients. She facilitates enterprise-level collaborations to develop robust patient-oriented risk management and governance frameworks.

Marilyn Metcalf

Marilyn Metcalf

Head, Center of Innovation & Patient Engagement Lead, GlaxoSmithKline

Read more

Dr. Metcalf is a Patient Engagement Lead at GSK. She and her Patients in Partnership colleagues lead GSK’s work developing medicines with patients, to meet their health goals. She is a member of GSK’s Global Safety Board and participates in a number of alliances including Patient Focused Medicine Development; Patients as Partners; FasterCures; National Health Council; National Academies of Sciences, Engineering, and Medicine; and TransCelerate.

Previously she was Family Health International’s project director for an NIH master contract for HIV vaccine research, primarily in developing countries. She studied the health economics and quality of life effects of HIV therapies at the former GlaxoWellcome. She moved to the UK to build GSK’s international Decision Sciences team. Upon returning to the US, she led Centocor’s R&D portfolio management team, formed GSK’s Benefit Risk Evaluation team, then led the Pharmacovigilance Centre of Innovation. Her current role began in June 2017.

Christine MacCracken

Christine MacCracken

Director, Patient Support, Janssen

Read more

Christine MacCracken is Director, Patient Support at the Janssen Pharmaceutical Companies of Johnson and Johnson where she leads strategic identification and implementation of patient-centered initiatives. In this role, she serves as key liaison to New York University School of Medicine and the Compassionate Use Advisory Committee (CompAC). Her focus is on raising organizational awareness around hearing the voice of the patient and recognizing “Every Patient is a Person First”.

Prior to joining the Johnson & Johnson Family of Companies in 2015, Christine was Senior Director, Business Insights at the National Comprehensive Cancer Network (NCCN).In support of people with cancer and the providers who treat them, she closely collaborated with industry, state oncology societies and advocacy groups to disseminate NCCN treatment information through health technology platforms as well as market and outcome research programs.

Christine’s strong passion around hearing the voice of the patient began at the Children’s Hospital of Philadelphia where she was an oncology nurse treating families with life changing diagnoses. With patients and their experience front of mind, she developed an interest in research and joined Radiation Therapy Oncology Group (RTOG) with a focus on quality of life studies. Bridging this interest with pharmaceutical development, she later joined Merck & Co., Inc. with increasing roles of responsibility in clinical research and academic affairs, ultimately sharing her collective experience as an adjunct professor.

Christine resides outside of Philadelphia with husband Tim, and the luckiest dog on earth, Jack. She holds a Bachelor of Science, Nursing from Holy Family University and Master’s Degree, Health Education from Arcadia University.

Jaye Bea Smalley

Jaye Bea Smalley

Associate Director, Patient Advocacy and Professional Relations - Patient Engagement, Boehringer Ingelheim

Read more

More information coming soon...

Madeline Geday

Madeline Geday

Associate Director, Patient and Stakeholder Engagement Lead, Merck

Read more

Madeline is an Associate Director for the Global Trial Optimization Group within GO (Global Operations) at Merck and Co., Inc. She serves as Patient and Stakeholder Engagement Lead for her organization. Madeline is responsible for optimizing clinical trial feasibility and execution through integrated data-driven expert analysis and recommendations, while promoting its engagement, development, and opportunities for innovation in recruitment and retention.

Madeline joined Merck in 2004. She began her work as a Medical Program Clinical Specialist working on several insomnia programs in clinical neuroscience with a focus on patient recruitment. Madeline joined Global Trial Optimization in 2006 where she has spearheaded dozens of patient recruitment initiatives, served as Therapeutic Area lead for Neuroscience, Ophthalmology, Hematology and Multiple Myeloma as well as Process Owner and Subject Matter Expert for the department. While at Merck, she has helped launch the Clinical Trials Microsite of merck.com; has lead several voice of the patient projects; and has served as an industry expert in the field of recruitment and retention. Most recently, she has been appointed to lead the initiative for Patient and Stakeholder Engagement within the Global Clinical Trial Organization with the intent of capturing the voice of the patient into operational aspects of clinical trial design, feasibility, and recruitment and retention. She also works on several collaborative projects surrounding Diversity in Clinical Trials. Trained in Health Literacy principles, she has used her knowledge and expertise to champion changes to patient facing materials to ensure health literacy for clinical trial participants and their families.

Prior to Merck, Madeline held positions in Business Development, Education, and in Clinical Research as a CRA Associate.

Madeline received her B.S. in Psychology and Health/Exercise Physiology from Ursinus College in Collegeville, Pennsylvania and is pursuing graduate coursework in Marketing from Temple University.

Barbara Wuebbels

Barbara Wuebbels

Vice President of Global Patient Relations, Audentes Therapeutics

Read more

Barbara has been involved in patient advocacy activities for patients with rare diseases for the past 15 years at Ucyclyd Pharma and BioMarin. She joined Audentes Therapeutics as Vice President of Patient Advocacy and Medical Affairs in 2013. Currently she is the Vice President of Global Patient Relations. She has been actively involved with the National Organization of Rare Diseases, International Conference of Rare Disorders, and the Global Genes Project. Currently she serves on the Board of the Batten’s Disease Support and Research Association. Additionally she is the Chair and founding board member of the Professional Patient Advocates in the Life Sciences.

She holds Bachelor’s and Masters degrees in nursing.

Aaron Mitchell

Aaron Mitchell

Managing Principal, ZS

Read more

Aaron Mitchell is a Managing Principal and the global lead for ZS’s R&D excellence practice, based in Zurich, Switzerland. He partners with clients to strengthen the value of their pipelines, optimize the execution of clinical trials, drive the effective use of real-world evidence, and improve medical and scientific engagement. A key area of focus for Aaron is patient-centric drug development, including optimizing clinical trials for patients and leveraging real-world evidence to support product development. Aaron joined ZS in January of 2003. Prior to ZS Aaron was a manager for Deloitte, providing strategic consulting services to clients in a range of industries including financial services consumer products retail and healthcare. He has a Master of Business Administration degree from the Haas School of Business at University of California Berkeley and a Bachelor of Science degree in mechanical engineering from the United States Military Academy at West Point.

Hensley Evans

Hensley Evans

Principal, ZS

Read more

Hensley Evans is a Principal based in New York and leads ZS’s patient marketing strategy practice. Hensley has developed and implemented strategic solutions that combine marketing efforts with consumer health support programs for pharmaceutical, biotech, over-the-counter and provider clients, and has driven health and wellness initiatives in the consumer goods industry. Hensley holds a B.A. in Economics from Duke University and an M.B.A from the University of Pennsylvania’s Wharton School of Business.

Roger Sawhney

Roger Sawhney

Senior Vice President of Life Sciences Strategy and Business Development, Outcome Health

Read more

As Senior Vice President of Life Sciences Strategy and Business Development, Roger leads Outcome Health’s efforts to develop relationships and partnerships with the world’s leading life sciences companies. With 20 years of experience in the biopharmaceutical industry, Roger focuses on developing, coordinating and implementing strategies to help Outcome Health’s brand partners meet their business goals.

Roger was previously a partner in Bain and Company’s global healthcare and private equity practices, where he enabled healthcare companies to drive strategic position and competitive advantage. He also worked at Novartis as senior vice president and global head of corporate strategy, leading the company’s long range planning, business growth and eHealth efforts, as well as emerging market strategy. He serves on the Board of Directors for the New York Institute of Technology (NYIT).

Heather Erickson

Heather Erickson

Chief of Staff, Sangamo Therapeutics

Read more

More information coming soon...

Gavin Corcoran

Gavin Corcoran

Chief Medical Officer, Allergan

Read more

More information coming soon...

Cathryn Clary

Cathryn Clary

Global Head, Patient Affairs and Policy, Chief Medical Office, Novartis

Read more

Cathryn M. Clary, MD is Global Head of Patient Affairs and Policy in the Chief Medical & Patient Safety Office, Novartis Global Drug Development. In this role, Cathryn is responsible for ensuring the implementation of Patient Focused Drug Development across Novartis and developing and implementing patient centered policies.

Cathryn received her MD degree from the University of Missouri-Columbia and completed psychiatric residency training at the University of Pennsylvania in Philadelphia.  She practiced psychiatry for 13 years in Delaware, staying actively engaged in clinical research through her membership in the University of Pennsylvania Psychopharmacology Research group.

After receiving an MBA degree from the University of Delaware, Cathryn joined Pfizer in 1996 as Medical Director. Her 13 year career at Pfizer was one of continued advancement and in her last four years, she served as SVP of the US Medical group.. supporting a large portfolio. After leaving Pfizer, Cathryn took a role as Head, US Clinical Development and Medical Affairs at Ipsen, a French biopharmaceutical company, for three years, before joining Novartis. 

Throughout her career, Cathryn has been interested and engaged in public affairs and public speaking on behalf of patients. This has led to engagements such as Congressional testimony on publications of pharmaceutical sponsored research in 2004 and presentations before the Institute of Medicine. She is a Distinguished Life Fellow of the American Psychiatric Association.  Cathryn has also published widely, mainly in psychiatric journals.

Martin Mendoza

Martin Mendoza

Director of Extramural Research, Office of Minority Health, FDA

Read more

Martin Mendoza, PhD serves as Director of Extramural Research in FDA’s Office of Minority Health (OMH) where he oversees OMH’s extramural research grant program. Martin has spoken before Congress and other audiences in support of OMH’s programs, has authored numerous Congressionally-mandated reports, and is primary author for OMH’s recent FDA guidance document Collection of Race and Ethnicity Data in Clinical Trials. Prior to FDA, he spent several years in NIH’s extramural and intramural research programs, with work ranging from neurological clinical trials, pediatric oncology research, to the Human Genome Project. Martin received his doctorate in cancer biology from Johns Hopkins University.

Divya Mishra Aidoud

Divya Mishra Aidoud

Associate Director, New Product Planning Market Research, Sanofi

Read more

Divya Aidoud is passionate about generating market knowledge and authentic understanding of consumers to help businesses create offerings that address real problems. For over 16 years, she has led the development of strategic learning plans that keep the consumer’s voice, center-stage.

Divya is currently Associate Director, New Product Planning Market Research for Sanofi Genzyme. Before this, she was Director, Global Market Research and Portfolio Management for Sanofi Biosurgery. In this role she developed a New Product Development commercial process and the first Global Patient Journey Playbook. Prior to Sanofi, Divya held global marketing research roles at Keurig, Proctor & Gamble, Boehringer Ingelheim, and Sunovian.

Divya holds a B.A. in Chemistry from Wellesley College and an MBA from Babson College. She is an avid yogi practitioner and is enjoying being a first-time mom.

Frank Spinelli

Frank Spinelli

Medical Director, Patient Affairs, US, ViiV Healthcare

Read more

More information coming soon...

Ramana Sonty

Ramana Sonty

Director of Strategy, Global Medical Organization, Janssen

Read more

Ramana Sonty, MBBS, PhD, is a Director of Strategy, in the Janssen Global Medical Organization.

Dr. Sonty is a J&J leader who helped launch Janssen’s innovative pilot with NYU called CompAC (Compassionate Use Advisory Committee). The CompAC is a first-of-its-kind independent, expert body providing recommendations on compassionate use requests. The model been expanded to all of Janssen’s assets and is under consideration for adoption more broadly across the industry. Pilot findings have been published in Nature and JAMA.  He has trained in Medicine and Neuroscience.

Debra Reinhard

Debra Reinhard

Lead, Translational Medicine Enabling Solutions, Bristol-Myers Squibb

Read more

A sought-after speaker and subject matter expert with over 28 years in the Pharmaceutical industry, Deb’s career has spanned Corporate and R&D Finance and strategy, as well as broad Informatics roles in support of R&D.  As Head of Translational Medicine Enabling Solutions, she leads a growing organization that plans and executes translational medicine strategies, integrating Discovery, Clinical Development and Translational Research.  She is responsible for the BMS biorepository, redesigning informed consent processes and tools, and ensuring robust operations across all lab partners.  Deb is a core member of TransCelerate’s eConsent initiative creating an industry-aligned position on consent processes and technologies.

Joseph Kim

Joseph Kim

Senior Advisor, Clinical Innovation, Eli Lilly and Company

Read more

Joseph Kim serves as a Senior Advisor in Clinical Innovation at Lilly, focusing on developing and implementing innovative patient engagement solutions. He has spent over 18 years in the Pharma industry utilizing a unique approach that integrates his experiences working for Sponsors such as Shire and Merck, CROs, and technology vendors. He has a robust combination of experience that includes early and late phase clinical research, and a well-known history of innovation in the clinical research industry, recognized as one of “Top 100 individuals on the 2015 MedicineMakers Power List, and “20 Innovators Changing the Face of the Clinical Trials Industry” by CenterWatch in 2013.  He holds a BS in Molecular Biology from Lehigh University and an MBA from Villanova. He can be reached at kim_joseph_p@lilly.com and on Twitter

Patricia Cunningham

Patricia Cunningham

Associate Director Health Information Technology, Boehringer Ingelheim

Read more

Ms. Cunningham has approximately 30 years of progressive experience in health information management and technology. She has a Masters Degree in Health Informatics, is a Certified Registered Health Information Administrator and is also Certified in Healthcare Privacy and Security. Her extensive career and experience includes implementing numerous EHR platforms in diverse healthcare settings; leading Health Information Management and Technology Teams; serving as the organization-wide Privacy Officer in a large academic medical center and serving as the Chief Technology Officer for the State of Illinois’ Health Information Exchange. In her current role as the Associate Director of Health IT at Boehringer-Ingeheim Pharmaceuticals, she is responsible for orchestrating digital processes for organizational population health initiatives.

Stephen Yates

Stephen Yates

Clinical Program Director and Head, Patient Engagement Strategy, UCB

Read more

More information coming soon...

Daniele D’Ambrosio

Daniele D’Ambrosio

Senior Director, Clinical Science Program Head, Actelion

Read more

Daniele D'Ambrosio, M.D., Ph.D., currently leads Actelion's clinical team developing ponesimod for the treatment of multiple sclerosis. Daniele joined Actelion in 2009 and was appointed Senior Director, Clinical Science Program Head in 2011. In his function, he has provided scientific and management leadership to Actelion's clinical programs in autoimmune diseases. Prior to joining Actelion, Daniele held various R&D positions in biotech and leading pharmaceutical companies Roche and Novartis.

Daniele earned his M.D. and Ph.D. in Experimental Medicine and Immunology from La Sapienza University, Rome, Italy. He completed a postdoctoral fellowship in Immunology at the National Jewish Hospital in Denver, has published more than 60 scientific articles, and is inventor on one issued patent. Daniele has served on the Editorial Board of British Journal of Pharmacology, and has held a Professorship at the School of medical, molecular and cellular biotechnologies at Vita Salute San Raffaele University, Milano, Italia

Luther Clark

Luther Clark

Global Director, Scientific, Medical and Patient Perspective, Merck

Read more

Dr. Luther T. Clark is Global Director, Scientific Medical and Patient Perspective (SMPP) in the Office of the Chief Patient Officer (OCPO) at Merck. In this role, he supports the needs of the CPO by (1) gathering internal and external scientific and medical information to assist with decision-making at the highest levels and (2) collaborating across Merck to help increase the voice of patients, directly and indirectly into decision-making across the enterprise. He is a key member of the team that champions the OCPO’s Health Care Equities Strategic Initiative (including promotion of health literacy and research diversity) and chairs the Health Literacy Investigator Initiated Studies Research Committee.

Prior to joining Merck, Dr. Clark was Chief of the Division of Cardiovascular Medicine and Director of the National Institutes of Health (NIH) funded Brooklyn Health Disparities Research Center.

Dr. Clark earned his Bachelor of Arts degree from Harvard College and his Medical degree from Harvard Medical School. He has authored more than 100 publications, edited and was principal contributor to the textbook, Cardiovascular Disease and Diabetes (McGraw-Hill 2007).

Mary Elmer

Mary Elmer

Associate Director, Global Patient Engagement Strategy Office, Merck

Read more

Mary Elmer leads a team for the global patient engagement program at the office for the Chief Patient Officer at Merck & Co., Inc. This group is actively involved in bringing the voice of the patient into the drug development process at Merck through strong collaborative partnerships with patients and organizations serving patients. Mary is a board-certified nurse practitioner with over 18 years of experience at Merck, working in all phases of drug development and implementing global strategic initiatives. Mary is a member of the Global Diversity and Inclusion council at Merck and co-leads the diversity in US clinical trials initiative, which seeks to ensure our clinical trials are representative of diverse patient groups. Mary is a member of TransCelerate Biopharma, and leads a work stream on patient engagement.

Mary obtained her Master of Science in Nursing degree from the University of Pennsylvania. She is a Six Sigma green belt who has experience in executing organizational change and cross-company initiatives, such as implementing clinical trial data sharing at Merck, in alignment with trade organizations (EFPIA/PHRMA) and regulatory bodies.

Martin Collyer

Martin Collyer

Chief Operating Officer Patient Recruitment, Bioclinica

Read more

 Martin Collyer is a senior healthcare and life sciences executive with more than 20 years of experience and a strong operations and finance background.

As COO of Bioclinica’s Patient Recruitment & Retention division, Martin enables organizations to expedite the enrollment of patients into clinical trials utilizing therapeutically-aligned global patient engagement platforms and digital methodologies.

Prior to joining Bioclinica in 2016 he was with Hitachi for four years solving big data challenges.

Susan Bartlett

Susan Bartlett

Principal, Bridgeable

Read more

Susan Bartlett is a service designer and business strategist at Bridgeable, where she helps organizations transform their business using service design. Susan leads multidisciplinary design teams as they understand the complex interactions people have with the world around them, and work to make those interactions more meaningful and effective. Her projects emphasize co-creation with a wide array of stakeholders, applying a holistic, systems-thinking lens to problem solving, and using service design to effect organizational change.

Martha Brumfield

Martha Brumfield

President and CEO, Critical Path Institute

Read more

Martha A. Brumfield, PhD, is President and CEO of Critical Path Institute, which advances drug development and regulatory science. Brumfield brings 20 years of experience from Pfizer Inc., where she was SVP, Worldwide Regulatory Affairs and Quality Assurance. She chaired the board for RAPS, and currently serves as Secretary on the Board of I-ACT for Children, and on the steering committee for Harvard/Brigham & Women’s Multi-Regional Clinical Trials Initiative. Brumfield earned a BS and MS in chemistry from Virginia Commonwealth University, a PhD in organic chemistry from the University of Maryland, served as a postdoctoral fellow at The Rockefeller University, and holds an appointment as Assistant Professor, University of Arizona College of Pharmacy.

Kelly Franchetti RN,CCRN,CEN

Kelly Franchetti RN,CCRN,CEN

Vice President, Global Patients Insights and Engagement, Patient-Centered Sciences, Mapi

Read more

A prolific author, presenter, lecturer, and thought leader in the realm of patient recruitment and retention, Kelly Franchetti leads Mapi’s Patient Insight and Engagement team and brings extensive experience in partnering with patient advocacy, and clinical research with a specialty in Rare Disease programs.

She is a leading developer of Patient Engagement solutions in the world of both clinical research and in therapeutic practice.

Ms. Franchetti has two decades of direct patient experience, gained in both hospital and industry settings, including CROs, healthcare technology, patient research, and hands-on patient care across multiple therapeutic areas.

Ms. Franchetti was an active critical care Registered Nurse for over 18 years and an experienced caregiver for children with rare disease for over 20 years. This experience translates into a keen understanding of how patients think regarding their treatment, giving her a singular perspective regarding the best way to approach patients and Health Care Practitioners. She maintains her nursing status at Temple Hospital to continue to grow her knowledge base regarding patient care.

In conjunction with her nursing career, Ms. Franchetti founded the New Jersey State Coalition of Safe Kids Worldwide, where she worked directly with both local and national legislators and regulators to change laws to enhance safety for children throughout the state and North America.

Ms. Franchetti has been involved in the development and moderation of advisory boards as well as patient, HCP, and KOL forums. She also has experience collaborating with Patient and Clinical Advocacy groups. Her experience allows her to provide significant insights into how patients regard their treatment options and how to best approach patient recruitment and retention strategies.

Franchetti currently sits on Mapi’s Patient Initiative ommittee along with the industry’s foremost leaders on Patient Centered Medical Affairs, Patient Centered Outcomes, and Research Experts from the Mapi Trust.

Cindy Geoghegan

Cindy Geoghegan

Principal, Patient and Partners LLC

Read more

A patient advocate and cancer survivor with decades of health policy, communications and capacity-building experience, Cindy Geoghegan founded Patient & Partners to ensure that the patient perspective is strategically integrated into industry, academic, government and non-profit efforts focused on patient outcomes and clinical benefit. She has founded, transformed and grown several patient-led non-profit organizations, and represents the patient perspective on research projects sponsored by government, academia and industry. She currently serves as an individual patient/caregiver representative on CTTI’s Steering Committee and as a team lead for CTTI’s Mobile Clinical Trials Stakeholder Perceptions project.

Grace Cordovano

Grace Cordovano

CEO, Enlightening Results

Read more

Upon recognizing significant unmet needs and challenges in patients’ journeys throughout their cancer diagnosis, Dr. Grace Cordovano founded Enlightening Results, LLC in 2010. As the culmination of her life’s experiential learning and education, Dr. Cordovano is dedicated to fostering private, personalized patient advocacy services, specializing in the cancer arena.  She strategically and empathetically guides her clients through survivorship or end-of-life care, ensuring they are armed with the most pertinent, medically credible, easy to understand information so as to make empowered decisions about their care. Grace is a firm believer in the continuous advancement and improvement of cancer patient experiences through the infusion of empathic design and thinking into current healthcare paradigms. A frequent questioner of the status quo, she leaves no stone or process unturned in her quest to improve overall patient experiences across the continuum of patient care. She's motivated to have patient and caregiver stories included throughout the entire healthcare ecosystem and considers herself a patient voice activator. Grace operates as part rocket scientist, part healthcare MacGyver, a dash of Tinkerbelle (because everything is better when left with a little sparkle), topped off with a whole lot of coffee. Grace is a proud member of the Alliance of Professional Health Advocates (APHA), the premier, international organization of independent professional patient advocates.

Heidi Floyd

Heidi Floyd

Author, Patient, Advocate, Speaker

Read more

As individuals are diagnosed with cancer, many immediately seek to make a connection with others for help.  Heidi Floyd has become that resource for many. As an author/speaker/patient/advocate, she is able to lean on myriad of NGOs and fellow patients in her network. Heidi has the ability to lean in and listen to true needs – from caregivers and corporations who want to help, but aren’t sure where to begin. Connecting those who need with those who can assist is her true passion, and has done so worldwide. She’s addressed venues as varied as Google to classrooms of 6.

Levi Gershkowitz

Levi Gershkowitz

Founder and Executive Director, Living in the Light LLC

Read more

As a compassionate writer and photographer with a love for people and the stories they carry, Levi is the Founder and Executive Director of Living in the Light, an advocacy corporation that utilizes the potency of photography, filmmaking and compelling personal narratives to educate about the realities of living with a rare disease and the unprecedented impact this has on families and daily life. This distinct concentration grew out of an understanding that the rare disease community is comprised of many people with many voices, while at the heart lies a unified experience of deep resilience and unique wisdom.

Michael Mittelman

Michael Mittelman

VP Patient Advocacy & Strategic Partnerships, American Living Organ Donor Fund

Read more

Michael Mittelman is currently the Patient Editor at The BMJ and a Co-Founder and VP of Patient Advocacy and Strategic Partnerships of the American Living Organ Donor Fund, a patient rights group focused on helping living organ donors in their quest to become a donor. He is the former CEO and Co-Founder of PHmHealth, a digital health company focused on post-acute care and compliance. His experience as a patient spans over 3 decades. He is a 3-time kidney transplant recipient with other chronic conditions. Michael was invited to testify/advocate before the FDA and serves as PCORI (Patient-Centered Outcomes Research Institute) patient representative. Additionally, he serves on the steering committee of a PCORI-funded initiative. He has also overseen the mobile app development taskforce and the data governance taskforce for the same PCORI-funded initiative, the NephCure Kidney Network. Michael is a tireless, independent patient advocate and a healthcare strategist. He strongly believes that patients should play integral roles in healthcare companies and government agencies.

Michael holds an MBA in Healthcare Management from the Fox School of Business at Temple University.  He also has a BA in Biological Basis of Behavior from the University of Pennsylvania. He is a published author, with his latest piece in the American Journal of Transplantation.

Marla Jan Wexler

MarlaJan Wexler

Patient, Lupus Advocate and Blogger, Luck Fupus

Read more

MarlaJan Wexler is 35 years old, was born with a complex congenital heart defect, and had 4 open-heart surgeries by the time she was 6. She went from pediatric cardiac ICU patient to pediatric cardiac ICU nurse until being diagnosed with systemic lupus erythematous (lupus). Due to complications from the disease, she was forced her to give up her nursing career. Since 2008 she has been diagnosed with lupus and multiple overlapping autoimmune diseases, cervical cancer, and underwent a double mastectomy December 2014 after a lump was found in her breast.

She’s the creator and author of the blog Luck Fupus (www.luckfupus.com) which she writes about the day-to-day and long-term struggles of living with multiple chronic illnesses. She’s know for her humorous, non-sugar coated, keep-it-real style of writing. Her blog was used as a platform to help her become a patient leader and influencer, and she now travels the country attending healthcare conferences, speaking publicly sharing her story, educating and advocating for patients across the globe.

Nadia Bodkin

Nadia Bodkin

Board Member, EDSers United Foundation

Read more

Nadia is a seasoned rare disease advocate. She served as the chairperson for Rare NJ and was the Executive Director for RDUF. She also founded and currently directs EDSers United, and is the current Corporate Engagement Manager for the Jansen’s Foundation. Nadia earned her Pharm.D. and Masters in Genetics from Rutgers University. In addition to leading the community outreach and engagement efforts for LITL, Nadia also formulates and implements collaborative programs specific to the particularities of the rare disease community for several groups dedicated to serving rare disease stakeholders.

Nancy Roach

Nancy Roach

Founder, Fight Colorectal Cancer

Read more

A cancer survivor and advocate, Nancy knows how to make a difference. Nancy has been involved with the colorectal cancer community since 1996 when her mother-in-law was diagnosed with rectal cancer, and was a co-founder of the Colon Cancer Alliance in 1999. She works with the gastrointestinal research community, government agencies, elected officials and corporations, always pushing on behalf of people touched by colorectal cancer. She has been affiliated with the National Cancer Institute Clinical Trials Working Group, GI Steering Committee and SPORE program, served on the Scientific Advisory Board for StandUp To Cancer along with the editorial board of the American Association of Cancer Research’s consumer magazine. She founded Fight Colorectal Cancer in 2005 in order to provide focus, infrastructure and support to the growing colorectal cancer advocacy movement. Nancy has been an active board member since 2005.

James Metcalf

James Metcalf

Patient

Read more

James resides in southeast Missouri and is passionate about clinical research.  He first participated in a clinical trial on asthma which was investigating the efficacy of a new inhaler.  Since then, he has participated in approximately 32 clinical trials covering everything from pain management techniques to allergy studies though a university “Volunteer for Health” program.   Having lost his mom to mixed dementia, he is very involved in dementia research and most recently has enrolled in a study designed to detect Alzheimer’s dementia in its earliest stage.  James also volunteers his time to participate on TransCelerate’s patient advisory boards, where he has the opportunity to provide his feedback, insights and ideas on solutions aimed at creating better informed patients and lessening the burden for patients in clinical trials.

Download the detailed event brochure

Complete speaker line-up • Program for all tracks & sessions • Audience breakdown